REGENERON PHARMACEUTICALS, INC. (REGN) Form 8-K — Oct 6, 2026
Regeneron and Sanofi signed a Sixth Amendment to their 2009 Antibody License and Collaboration Agreement on October 1, 2026, adding four new long-acting Regeneron-invented antibodies targeting IL-13, IL-4, IL-4Rα, and an IL-4xIL-13 bispecific to the co-development and co-commercialization collaboration. Under the deal, Sanofi pays Regeneron $1.0 billion upfront, with up to $7.0 billion more in development, regulatory, and commercial milestones, and global profits on the new products will be split equally. Regeneron leads development and U.S. regulatory efforts, while Sanofi leads ex-U.S.
Key figures
- Deal Value Usd
- up to $8.0 billion ($1.0B upfront + up to $7.0B milestones)
- Profit split
- 50/50 on New Licensed Products
- Iprd eps impact
- approximately -$0.18 per diluted share
- Upfront payment
- $1.0 billion
- Milestone payments
- up to $7.0 billion
- Q3 2026 iprd charge pretax
- approximately $22 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.